AL-335 + odalasvir

**AL-335 + odalasvir** is an investigational oral combination therapy composed of two direct-acting antiviral agents targeting chronic hepatitis C virus (HCV) infection. AL-335 is a pangenotypic uridine nucleotide analog prodrug that acts as an HCV NS5B polymerase inhibitor, thereby inhibiting viral RNA synthesis. Odalasvir is a second-generation inhibitor of the HCV NS5A protein, which is essential for viral replication and assembly. Both agents, when combined, are intended to block different stages of the HCV replication cycle. The combination has been evaluated for efficacy, safety, and pharmacokinetics in Phase 1 and Phase 2 trials for HCV, primarily in patients without cirrhosis and various genotypes of the virus[3][5][6][9].